A New Era of Management of Von Hippel–Lindau Disease–Associated Tumors With Belzutifan

Belzutifan is a first-in-class hypoxia-inducible factor 2 alpha, or HIF-2 alpha, inhibitor drug for the treatment of hemangioblastomas of the central nervous system and pancreatic neuroendocrine tumors in adults with von Hipp.

Authors

Institutions

Publication Details

Journal
Clinical journal of oncology nursing
Published
2025-02-01
DOI
https://doi.org/10.1188/25.cjon.25-29
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A New Era of Management of Von Hippel–Lindau Disease–Associated Tumors With Belzutifan

Heather Niccum Haag
Clinical journal of oncology nursing
Cancer, Hypoxia, and Metabolism
article

A New Era of Management of Von Hippel–Lindau Disease–Associated Tumors With Belzutifan

Heather Niccum Haag
article en

Abstract

Belzutifan is a first-in-class hypoxia-inducible factor 2 alpha, or HIF-2 alpha, inhibitor drug for the treatment of hemangioblastomas of the central nervous system and pancreatic neuroendocrine tumors in adults with von Hipp.

Clinical journal of oncology nursingVol. 29(1)
Haywards Heath Hospital (GB)
Openalex Percentile: Top 97%
Cancer, Hypoxia, and Metabolism
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A New Era of Management of Von Hippel–Lindau Disease–Associated Tumors With Belzutifan — Heather Niccum Haag · Clinical journal of oncology nursing (2025) | TGRS Research Map | TGRS